GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,590,000 shares, a growth of 6.7% from the March 15th total of 1,490,000 shares. Based on an average trading volume of 367,100 shares, the short-interest ratio is currently 4.3 days.
GlycoMimetics Price Performance
GlycoMimetics stock opened at $2.28 on Thursday. The firm’s fifty day moving average price is $2.87 and its 200 day moving average price is $2.30. The company has a market capitalization of $146.95 million, a price-to-earnings ratio of -3.93 and a beta of 2.18. GlycoMimetics has a 12-month low of $1.11 and a 12-month high of $3.53.
Institutional Investors Weigh In On GlycoMimetics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its position in shares of GlycoMimetics by 20.4% during the 2nd quarter. Renaissance Technologies LLC now owns 566,400 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 95,800 shares during the last quarter. Millennium Management LLC boosted its stake in GlycoMimetics by 7.5% during the 2nd quarter. Millennium Management LLC now owns 434,655 shares of the biotechnology company’s stock valued at $260,000 after purchasing an additional 30,466 shares during the period. Vanguard Group Inc. boosted its stake in GlycoMimetics by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,879,412 shares of the biotechnology company’s stock valued at $1,037,000 after purchasing an additional 32,650 shares during the period. Dimensional Fund Advisors LP acquired a new position in GlycoMimetics during the 4th quarter valued at about $225,000. Finally, Geode Capital Management LLC boosted its stake in GlycoMimetics by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 405,335 shares of the biotechnology company’s stock valued at $1,228,000 after purchasing an additional 46,940 shares during the period. Institutional investors own 75.19% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on GlycoMimetics
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.
Featured Stories
- Five stocks we like better than GlycoMimetics
- The 3 Best Blue-Chip Stocks to Buy Now
- United Airlines Soars on Earnings Beat
- Options Trading – Understanding Strike Price
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What Are Dividend Challengers?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.